Estrogen-Receptor Negative Breast Cancer disease: Malacards - Research Articles, Drugs, Genes, Clinical Trials

MCID: EST002 MIFTS: 44	Estrogen-Receptor Negative Breast Cancer Categories: Cancer diseases	Data Licensing For inquiries, contact: [email protected]
Genes Tissues Related diseases Publications Drugs Expand all tables

Sources

Aliases & Classifications for Estrogen-Receptor Negative Breast Cancer

MalaCards integrated aliases for Estrogen-Receptor Negative Breast Cancer:

Name: Estrogen-Receptor Negative Breast Cancer ¹¹ ¹⁴ ¹⁶

Classifications:

MalaCards categories:
Global: Cancer diseases

See all MalaCards categories (disease lists)

External Ids:

Disease Ontology ¹¹ DOID:0060076

EFO ¹⁶ EFO_1000650

Sources

Summaries for Estrogen-Receptor Negative Breast Cancer

Disease Ontology: ¹¹ A breast cancer that is characterized by the absence of estrogen receptors.

MalaCards based summary: Estrogen-Receptor Negative Breast Cancer is related to hereditary breast cancer and body mass index quantitative trait locus 11. An important gene associated with Estrogen-Receptor Negative Breast Cancer is ESR1 (Estrogen Receptor 1), and among its related pathways/superpathways are ERK Signaling and Signal Transduction. The drugs Gemcitabine and Progesterone have been mentioned in the context of this disorder. Affiliated tissues include breast, brain and lymph node, and related phenotypes are Decreased viability and Decreased viability in pancreas lineage

Sources

Related Diseases for Estrogen-Receptor Negative Breast Cancer

Diseases in the Estrogen-Receptor Positive Breast Cancer family:

Estrogen-Receptor Negative Breast Cancer

Diseases related to Estrogen-Receptor Negative Breast Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 430)

#	Related Disease	Score	Top Affiliating Genes
1	hereditary breast cancer	30.6	CDH1 BRCA2 BRCA1
2	body mass index quantitative trait locus 11	29.9	TP53 STAT3 MIR10B H2AC18 ESR1 CYP19A1
3	breast cancer	29.8	TP53 STAT3 PGR MYC MIR373 MIR10B
4	colonic benign neoplasm	29.3	TP53 STAT3 MYC H2AC18 ESR1 ERBB2
5	estrogen-receptor positive breast cancer	29.3	TP53 STAT3 PGR ORAI3 MYC H2AC18
6	peripheral nervous system disease	29.2	TP53 STAT3 MYC H2AC18 ESR1 ERBB2
7	colorectal cancer	28.5	TP53 STAT3 PGR MYC MIR10B H2AC18
8	ovarian cancer	28.5	TP53 STAT3 PGR MYC MIR10B H2AC18
9	uterine corpus adenosarcoma	10.4	PGR ESR1
10	adult cystic nephroma	10.4	PGR ESR1
11	vagina leiomyosarcoma	10.4	PGR ESR1
12	vulvar benign neoplasm	10.4	PGR ESR1
13	adenosquamous breast carcinoma	10.4	TP53 PGR
14	lipid-rich breast carcinoma	10.4	PGR ERBB2
15	her2-receptor negative breast cancer	10.4	PGR ERBB2
16	nipple carcinoma	10.4	PGR ESR1 ERBB2
17	breast mucinous cystadenocarcinoma	10.4	PGR ESR1 ERBB2
18	breast fibroadenosis	10.4	PGR ESR1 ERBB2
19	bulbospinal polio	10.4	PGR ESR1 ERBB2
20	spinal polio	10.4	PGR ESR1 ERBB2
21	glycogen-rich clear cell breast carcinoma	10.4	PGR ESR1 ERBB2
22	breast cystic hypersecretory carcinoma	10.4	PGR ESR1 ERBB2
23	oncocytic breast carcinoma	10.4	PGR ESR1 ERBB2
24	breast squamous cell carcinoma	10.4	PGR ESR1 ERBB2
25	breast papillary carcinoma	10.4	PGR ESR1 ERBB2
26	malignant spiradenoma	10.4	TP53 ESR1
27	cervical adenocarcinoma	10.4	TP53 PGR ESR1
28	progesterone resistance	10.4	PGR ESR1
29	hereditary site-specific ovarian cancer syndrome	10.4	BRCA2 BRCA1
30	ovary transitional cell carcinoma	10.4	BRCA2 BRCA1
31	lipid-rich carcinoma	10.4	PGR ESR1 ERBB2
32	breast adenoid cystic carcinoma	10.4	PGR ESR1 ERBB2
33	progesterone-receptor negative breast cancer	10.4	PGR ESR1 ERBB2
34	bartholin's gland adenoma	10.4	TP53 PGR ESR1
35	bartholin's gland benign neoplasm	10.4	TP53 PGR ESR1
36	vestibular gland benign neoplasm	10.4	TP53 PGR ESR1
37	glycogen-rich carcinoma	10.4	PGR ERBB2
38	microglandular adenosis	10.4	PGR ESR1 ERBB2
39	apocrine adenosis of breast	10.4	TP53 ERBB2
40	apocrine sweat gland neoplasm	10.4	PGR ESR1 ERBB2
41	intraductal papilloma	10.4	PGR ESR1 ERBB2
42	bizarre leiomyoma	10.4	TP53 PGR ESR1
43	endometrial squamous cell carcinoma	10.4	TP53 PGR
44	diffuse peritoneal leiomyomatosis	10.3	PGR ESR1 CYP19A1
45	peritoneal benign neoplasm	10.3	PGR ESR1 CYP19A1
46	cervical adenosarcoma	10.3	TP53 PGR ESR1
47	endometrial stromal tumor	10.3	PGR H2AC18 ESR1
48	urethral benign neoplasm	10.3	TP53 PGR ESR1
49	cancerophobia	10.3	BRCA2 BRCA1
50	49, xxxxy syndrome	10.3

Graphical network of the top 20 diseases related to Estrogen-Receptor Negative Breast Cancer:

Sources

Symptoms & Phenotypes for Estrogen-Receptor Negative Breast Cancer

GenomeRNAi Phenotypes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

²⁵ (show all 11)

#	Description	GenomeRNAi Source Accession	Score	Top Affiliating Genes
1	Decreased viability	GR00055-A-1	9.98	EGFR
2	Decreased viability	GR00055-A-2	9.98	EGFR
3	Decreased viability	GR00221-A-1	9.98	AKT1 CDH1 EGFR ESR1 MYC
4	Decreased viability	GR00221-A-2	9.98	AKT1 ESR1
5	Decreased viability	GR00221-A-3	9.98	AKT1 MYC
6	Decreased viability	GR00221-A-4	9.98	AKT1 EGFR ESR1
7	Decreased viability	GR00249-S	9.98	AKT1 MYC
8	Decreased viability	GR00301-A	9.98	CDH1
9	Decreased viability	GR00386-A-1	9.98	ESR1
10	Decreased viability	GR00402-S-2	9.98	CDH1 ESR1 MYC
11	Decreased viability in pancreas lineage	GR00235-A	8.92	CCND1 GPER1 PGR TP53

MGI Mouse Phenotypes related to Estrogen-Receptor Negative Breast Cancer:

⁴⁵ (show all 20)

#	Description	MGI Source Accession	Score	Top Affiliating Genes
1	normal	MP:0002873	10.43	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
2	homeostasis/metabolism	MP:0005376	10.4	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
3	neoplasm	MP:0002006	10.37	AKT1 BRCA1 BRCA2 CCND1 CDH1 EGFR
4	endocrine/exocrine gland	MP:0005379	10.37	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
5	growth/size/body region	MP:0005378	10.36	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
6	muscle	MP:0005369	10.27	AKT1 BRCA1 CYP19A1 EGFR ERBB2 ESR1
7	cellular	MP:0005384	10.25	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
8	digestive/alimentary	MP:0005381	10.23	BRCA1 BRCA2 CCND1 CDH1 CYP19A1 EGF
9	embryo	MP:0005380	10.22	AKT1 BRCA1 BRCA2 CDH1 EGFR ERBB2
10	cardiovascular system	MP:0005385	10.22	AKT1 BRCA1 CCND1 CDH1 CYP19A1 EGFR
11	immune system	MP:0005387	10.21	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
12	limbs/digits/tail	MP:0005371	10.2	BRCA1 BRCA2 EGFR ERBB2 ESR1 GPER1
13	no phenotypic analysis	MP:0003012	10.18	CDH1 EGFR ESR1 GPER1 MIR10B MYC
14	liver/biliary system	MP:0005370	10.16	AKT1 CYP19A1 EGFR ESR1 GPER1 MYC
15	adipose tissue	MP:0005375	10.14	AKT1 BRCA1 CYP19A1 EGFR ESR1 MYC
16	reproductive system	MP:0005389	10.13	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
17	skeleton	MP:0005390	10	AKT1 BRCA1 BRCA2 CCND1 CYP19A1 EGFR
18	respiratory system	MP:0005388	9.92	AKT1 BRCA1 CCND1 EGFR ERBB2 ESR1
19	hematopoietic system	MP:0005397	9.77	AKT1 BRCA1 BRCA2 CCND1 CYP19A1 EGFR
20	integument	MP:0010771	9.47	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1

Sources

Drugs & Therapeutics for Estrogen-Receptor Negative Breast Cancer

Drugs for Estrogen-Receptor Negative Breast Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 103)

Name

Status

Phase

Clinical Trials

Cas Number

PubChem Id

Gemcitabine

Approved

Phase 2, Phase 3

95058-81-4, 122111-03-9

60750

Progesterone

Approved, Vet_approved

Phase 2, Phase 3

57-83-0

5994

Antiviral Agents

Phase 2, Phase 3

Anti-Infective Agents

Phase 2, Phase 3

Bevacizumab

Approved, Investigational

Phase 2

216974-75-3

135329020

Lenograstim

Approved, Investigational

Phase 2

135968-09-1

Letrozole

Approved, Investigational

Phase 2

112809-51-5

3902

Vinorelbine

Approved, Investigational

Phase 2

71486-22-1

44424639 60780

Sodium citrate

Approved, Investigational

Phase 2

68-04-2

23431961

Levoleucovorin

Approved, Experimental, Investigational

Phase 2

68538-85-2, 58-05-9, 73951-54-9

149436 6006

Methotrexate

Approved

Phase 2

1959-05-2, 59-05-2

4112 126941

Capecitabine

Approved, Investigational

Phase 2

154361-50-9

60953

Trastuzumab

Approved, Investigational

Phase 2

180288-69-1

Medroxyprogesterone acetate

Approved, Investigational

Phase 2

520-85-4, 71-58-9

6279 10631

Busulfan

Approved, Investigational

Phase 2

55-98-1

2478

Melphalan

Approved

Phase 2

148-82-3

4053 460612

Aldesleukin

Approved

Phase 2

110942-02-4

Thiotepa

Approved, Investigational

Phase 2

52-24-4

5453

Mechlorethamine

Approved, Investigational

Phase 2

51-75-2

4033

Sargramostim

Approved, Investigational

Phase 2

123774-72-1

Palbociclib

Approved, Investigational

Phase 2

571190-30-2

5330286

Cyclophosphamide

Approved, Investigational

Phase 2

50-18-0, 6055-19-2

2907

Pembrolizumab

Approved

Phase 2

1374853-91-4

254741536

Decitabine

Approved, Investigational

Phase 2

2353-33-5

451668

Dasatinib

Approved, Investigational

Phase 2

302962-49-8

3062316

Carboplatin

Approved

Phase 2

41575-94-4

10339178 38904

Paclitaxel

Approved, Vet_approved

Phase 2

33069-62-4

36314

Doxorubicin

Approved, Investigational

Phase 2

23214-92-8

31703

Epirubicin

Approved

Phase 2

56420-45-2

41867

Cisplatin

Approved

Phase 1, Phase 2

15663-27-1

2767 5702198 441203

Tamoxifen

Approved

Phase 2

10540-29-1, 54965-24-1

2733526

Anastrozole

Approved, Investigational

Phase 2

120511-73-1

2187

Folic acid

Approved, Nutraceutical, Vet_approved

Phase 2

59-30-3

6037

Citric acid

Approved, Nutraceutical, Vet_approved

Phase 2

77-92-9

311

D-Phenylalanine

Approved, Experimental, Investigational, Nutraceutical

Phase 2

63-91-2, 673-06-3

6140 71567

Saracatinib

Investigational

Phase 2

379231-04-6

10302451

Veliparib

Investigational

Phase 2

912444-00-9

11960529

Molgramostim

Investigational

Phase 2

99283-10-0

Entinostat

Investigational

Phase 2

209783-80-2

4261

Immunoglobulins, Intravenous

Phase 2

Immunoglobulins

Phase 2

Angiogenesis Inhibitors

Phase 2

Antibodies, Monoclonal

Phase 2

Antibodies

Phase 2

Folic Acid Antagonists

Phase 2

Folate

Phase 2

Vitamin B9

Phase 2

Estrogen Receptor Modulators

Phase 2

Vitamin B Complex

Phase 2

Dermatologic Agents

Phase 2

Interventional clinical trials:

(show all 24)

#	Name	Status	NCT ID	Phase	Drugs
1	A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer	Completed	NCT01881230	Phase 2, Phase 3	nab-Paclitaxel;Carboplatin;Gemcitabine
2	Effect of Preoperative Breast MRI on Surgical Outcomes, Costs and Quality of Life of Women With Breast Cancer	Active, not recruiting	NCT01805076	Phase 3
3	Phase II Neoadjuvant Trial With Carboplatin and Eribulin Mesylate in Triple Negative Breast Cancer Patients	Unknown status	NCT01372579	Phase 2	eribulin mesylate;carboplatin
4	A Phase II Study of AZD0530 in Hormone Receptor-Negative, Metastatic or Unresectable, Locally Advanced Breast Cancer	Completed	NCT00559507	Phase 2	saracatinib
5	Combined Targeted Therapies for Triple Negative Advanced Breast Cancer - A Phase II Trial of Weekly Nab-Paclitaxel and Bevacizumab Followed by Maintenance Targeted Therapy With Bevacizumab and Erlotinib	Completed	NCT00733408	Phase 2	paclitaxel albumin-stabilized nanoparticle formulation;erlotinib hydrochloride
6	A Study of Weekly Doxorubicin and Daily Oral Cyclophosphamide Plus G-CSF Followed by Weekly Paclitaxel as Neoadjuvant Therapy for Resectable, Hormone Receptor Negative or Hormone Receptor Positive, HER-2/Neu Positive Breast Cancer Followed by a Novel Regimen of Capecitabine, Methotrexate and Vinorelbine for Patients Who Do Not Have Either a Macroscopic or Microscopic Pathologic Complete Response, a Phase II Study	Completed	NCT00194779	Phase 2	doxorubicin hydrochloride;cyclophosphamide;paclitaxel;capecitabine;methotrexate;vinorelbine tartrate;tamoxifen citrate;letrozole
7	MPA Revisited: A Phase II Study of Anti-Metastatic, Anti-Angiogenic Therapy in Postmenopausal Patients With Hormone Receptor Negative Breast Cancer. A Translational Breast Cancer Research Consortium (TBCRC) Trial	Completed	NCT00577122	Phase 2	Medroxyprogesterone progesterone acetate (MPA);Medroxyprogesterone with Cyclophosphamide + Methotrexate
8	A Phase II Trial for Patients With Inflammatory (Stage IIIB) and Responsive Metastatic Stage IV Breast Cancer Using Busulfan, Melphalan and Thiotepa Followed by Autologous or Syngeneic PBSC Rescue and 12 Weeks of Post-Engraftment Immunotherapy With Low-Dose IL-2 and GM-CSF	Completed	NCT00003199	Phase 2	tamoxifen citrate;busulfan;thiotepa;melphalan
9	Phase II Trial of the Cyclin-Dependent Kinase Inhibitor PD 0332991 in Patients With Cancer	Completed	NCT01037790	Phase 2	PD-0332991
10	An Adaptive, Randomized Phase II Trial to Determine Pathologic Complete Response With the Addition of Carboplatin With and Without Veliparib to Standard Chemotherapy in the Neoadjuvant Treatment of Triple-Negative Breast Cancer	Completed	NCT01818063	Phase 2	Paclitaxel;Carboplatin;Doxorubicin;Cyclophosphamide;Veliparib
11	A Phase 2 Study of VLS-101 in Patients With Solid Tumors	Recruiting	NCT04504916	Phase 2	Zilovertamab vedotin
12	T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant Chemotherapy	Active, not recruiting	NCT02957968	Phase 2	Doxorubicin;Cyclophosphamide;Paclitaxel;Carboplatin;Decitabine;Pembrolizumab
13	Phase II Short-term Adjuvant Therapy and Biomarker Studies With Targeted Agents in Women With Estrogen Receptor Negative Breast Cancer	Active, not recruiting	NCT01471106	Phase 2	Dasatinib
14	A Phase 2 Trial of Liposomal Doxorubicin and Carboplatin in Patients With ER, PR, HER2 Negative Breast Cancer (TNBC)	Suspended	NCT02315196	Phase 2	pegylated liposomal doxorubicin hydrochloride;epirubicin hydrochloride;carboplatin;paclitaxel
15	A Phase Ib/II Trial of GDC-0941 (a PI3K Inhibitor) in Combination With Cisplatin in Patients With Androgen Receptor Negative Triple Negative Metastatic Breast Cancer	Terminated	NCT01918306	Phase 1, Phase 2	cisplatin;GDC -0941
16	GCC 0927 A Pilot and Phase II Study of Entinostat and Anastrozole/Tamoxifen in Women With Triple Negative Breast Cancer to Evaluate Biomarkers and Surrogates for Response	Terminated	NCT01234532	Phase 2	entinostat;anastrozole
17	A Phase II Study of RO4929097 (IND 109291) in Advanced, Metastatic, or Recurrent Triple Negative Invasive Breast Carcinoma	Terminated	NCT01151449	Phase 2	gamma-secretase/Notch signalling pathway inhibitor RO4929097
18	A Phase II Study of the Feasibility and Efficacy of Breast Conserving Surgery in Patients With MRI Detected Multi-Centric Breast Cancer	Withdrawn	NCT01100489	Phase 2
19	Phase IB Randomized, Double-Blinded, Placebo-Controlled, Dose Escalation Study of Polyphenon E in Women With a History of Hormone Receptor-Negative Breast Cancer	Completed	NCT00516243	Phase 1	defined green tea catechin extract
20	Phase I Study of ABT-888 in Combination With Cisplatin and Vinorelbine for Patients With Advanced Triple Negative Breast Cancer and/or BRCA-Mutation Associated Breast Cancer	Completed	NCT01104259	Phase 1	veliparib;cisplatin;vinorelbine tartrate
21	A Phase I Study of UCN-01 in Combination With Irinotecan in Resistant Solid Tumor Malignancies (Part I) and in Triple Negative (ER-Negative, PgR-Negative, HER-2 Not-Amplified) Recurrent Breast Cancers (Part II)	Completed	NCT00031681	Phase 1	7-hydroxystaurosporine;irinotecan hydrochloride
22	Two Phase I Studies in Patients With Brain Metastases From Any Primary Histology, Followed by a Randomized Phase 2 Study of RO4929097 Combined With CNS Radiotherapy in Patients With Brain Metastases From Breast Cancer Whose Tumors Are Estrogen Receptor Negative	Terminated	NCT01217411	Phase 1	Gamma-secretase/Notch signalling pathway inhibitor RO4929097
23	Estrogen Receptor (ER) PET/CT Imaging in Breast Cancer	Recruiting	NCT05541367
24	A Pilot Study of the Effect of Erlotinib (Tarceva®) on Biomarkers in Estrogen Receptor Negative Breast Cancer Expressing the Epidermal Growth Factor Receptor and Interleukin 1α	Terminated	NCT00503841		erlotinib hydrochloride

Search NIH Clinical Center for Estrogen-Receptor Negative Breast Cancer

Sources

Genetic Tests for Estrogen-Receptor Negative Breast Cancer

Sources

Anatomical Context for Estrogen-Receptor Negative Breast Cancer

Organs/tissues related to Estrogen-Receptor Negative Breast Cancer:

MalaCards : Breast, Brain, Lymph Node, Prostate, Colon, Lung, Ovary

Sources

Publications for Estrogen-Receptor Negative Breast Cancer

Articles related to Estrogen-Receptor Negative Breast Cancer:

(show top 50) (show all 355)

#	Title	Authors	PMID	Year
1	Burden of lymphedema in long-term breast cancer survivors by race and age. ⁶²	Ren Y...Troester MA	36223240	2022
2	Everolimus for Estrogen Receptor-negative Breast Cancer Prevention: A Journey Begun? ⁶²	Nye L...Khan SA	36453053	2022
3	Twist alters the breast tumor microenvironment via choline kinase to facilitate an aggressive phenotype. ⁶²	Vesuna F...Raman V	36136285	2022
4	Survival and clinicopathological significance of blood vessel invasion in operable breast cancer: a systematic review and meta-analysis. ⁶²	Lin Y...Pang D	36156086	2022
5	RE: Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. ⁶²	Krieger N	35377448	2022
6	EGF-Dependent Activation of ELK1 Contributes to the Induction of CLDND1 Expression Involved in Tight Junction Formation. ⁶²	Matsuoka H...Michihara A	35892692	2022
7	ZBED2 expression enhances interferon signaling and predicts better survival of estrogen receptor-negative breast cancer patients. ⁶²	Liu D...Wu Y	35486908	2022
8	Uncoiling the link between STIM1 and metastatic pathways in estrogen receptor negative breast cancer cells. ⁶²	Monteith GR...Roberts-Thomson SJ	35180509	2022
9	Lipid exposure activates gene expression changes associated with estrogen receptor negative breast cancer. ⁶²	Yadav S...Clare SE	35508495	2022
10	Photoacoustic Tomography Detects Response and Resistance to Bevacizumab in Breast Cancer Mouse Models. ⁶²	Quiros-Gonzalez I...Bohndiek SE	35404400	2022
11	Two distinct mechanisms underlie estrogen-receptor-negative breast cancer susceptibility at the 2p23.2 locus. ⁶²	Mendoza-Fandino G...Monteiro ANA	34803163	2022
12	27-Hydroxycholesterol Binds GPER and Induces Progression of Estrogen Receptor-Negative Breast Cancer. ⁶²	Avena P...Shaul PW	35326671	2022
13	Nuclear Localization of Fibroblast Growth Factor Receptor 1 in Breast Cancer Cells Interacting with Cancer Associated Fibroblasts. ⁶²	Suh J...Surh YJ	35419302	2022
14	Decreasing Incidence of Estrogen Receptor-Negative Breast Cancer in the United States: Trends by Race and Region. ⁶²	Davis Lynn BC...Rosenberg PS	34508608	2022
15	Associations of genetically proxied inhibition of HMG-CoA reductase, NPC1L1, and PCSK9 with breast cancer and prostate cancer. ⁶²	Sun L...Zhu Z	35151363	2022
16	The Effect of Estrogen Receptor Status on Survival in Breast Cancer Patients in Ethiopia. Retrospective Cohort Study. ⁶²	Belete AM...Shiferaw WS	35747466	2022
17	Proteomic Analysis Identifies p62/SQSTM1 as a Critical Player in PARP Inhibitor Resistance. ⁶²	Uddin MH...Wu GS	35847859	2022
18	Investigation of Chemopreventive and Antiproliferative Potential of Dicliptera roxburghiana. ⁶²	Ahmad B...Khattak A	34991410	2022
19	Perfluorooctanoic acid (PFOA) as a stimulator of estrogen receptor-negative breast cancer MDA-MB-231 cell aggressiveness: Evidence for involvement of fatty acid 2-hydroxylase (FA2H) in the stimulated cell migration. ⁶²	Sakai G...Takeda S	35370244	2022
20	Exploiting off-target effects of estrogen deprivation to sensitize estrogen receptor negative breast cancer to immune killing. ⁶²	Wolfson B...Hodge JW	34244306	2021
21	Comparison of the Prevalence of Pathogenic Variants in Cancer Susceptibility Genes in Black Women and Non-Hispanic White Women With Breast Cancer in the United States. ⁶²	Domchek SM...CARRIERS Consortium	34042955	2021
22	The analog of cGAMP, c-di-AMP, activates STING mediated cell death pathway in estrogen-receptor negative breast cancer cells. ⁶²	Vasiyani H...Singh R	33840002	2021
23	Aberrant transcriptional and post-transcriptional regulation of SPAG5, a YAP-TAZ-TEAD downstream effector, fuels breast cancer cell proliferation. ⁶²	Canu V...Blandino G	33230261	2021
24	Syndecan-4 as a Pathogenesis Factor and Therapeutic Target in Cancer. ⁶²	Onyeisi JOS...Gotte M	33810567	2021
25	A Population-Based Study of Genes Previously Implicated in Breast Cancer. ⁶²	Hu C...Couch FJ	33471974	2021
26	Stratification of Estrogen Receptor-Negative Breast Cancer Patients by Integrating the Somatic Mutations and Transcriptomic Data. ⁶²	Hou J...Li C	33613637	2021
27	Calcitriol induces estrogen receptor α expression through direct transcriptional regulation and epigenetic modifications in estrogen receptor-negative breast cancer cells. ⁶²	Santos-Martinez N...Garcia-Becerra R	35018235	2021
28	Cryptotanshinone Inhibits ERα-Dependent and -Independent BCRP Oligomer Formation to Reverse Multidrug Resistance in Breast Cancer. ⁶²	Ni W...Lu Y	33968724	2021
29	Uncovering Tumor-Stroma Inter-relationships Using MALDI Mass Spectrometry Imaging. ⁶²	Boyle ST...Klingler-Hoffmann M	32870688	2020
30	Polycystic ovary syndrome is causally associated with estrogen receptor-positive instead of estrogen receptor-negative breast cancer: a Mendelian randomization study. ⁶²	Wu PF...Lin Y	32413428	2020
31	Coexpression of PBX1 and EMP2 as Prognostic Biomarkers in Estrogen Receptor-Negative Breast Cancer via Data Mining. ⁶²	Qiu Y...Wu Y	32216630	2020
32	GLIS1, a novel hypoxia-inducible transcription factor, promotes breast cancer cell motility via activation of WNT5A. ⁶²	Shimamoto K...Hirohashi N	32047936	2020
33	Circulating miRNAs in HER2-Positive and Triple Negative Breast Cancers: Potential Biomarkers and Therapeutic Targets. ⁶²	Gupta I...Al Farsi H	32942528	2020
34	Personal use of permanent hair dyes and cancer risk and mortality in US women: prospective cohort study. ⁶²	Zhang Y...Schernhammer ES	32878860	2020
35	Leptin Signaling Affects Survival and Chemoresistance of Estrogen Receptor Negative Breast Cancer. ⁶²	Lipsey CC...Gonzalez-Perez RR	32471192	2020
36	CDDO-Me Alters the Tumor Microenvironment in Estrogen Receptor Negative Breast Cancer. ⁶²	Ball MS...Pioli PA	32300202	2020
37	Development of a nine-lncRNA signature as a novel prognostic marker of estrogen receptor-negative breast cancer. ⁶²	Wang Z...Wei M	32218854	2020
38	G protein-coupled kisspeptin receptor induces metabolic reprograming and tumorigenesis in estrogen receptor-negative breast cancer. ⁶²	Dragan M...Bhattacharya M	32034133	2020
39	Prediction of Successful Ovarian Protection Using Gonadotropin-Releasing Hormone Agonists During Chemotherapy in Young Estrogen Receptor-Negative Breast Cancer Patients. ⁶²	Lee DY...Kim SW	32656076	2020
40	Metformin and Chemoprevention: Potential for Heart-Healthy Targeting of Biologically Aggressive Breast Cancer. ⁶²	Jones VC...Seewaldt VL	33194937	2020
41	Cytotoxic, anti-proliferative and apoptotic effects of noscapine on human estrogen receptor positive (MCF-7) and negative (MDA-MB-231) breast cancer cell lines. ⁶²	Kocak C...Vatansev H	31950839	2020
42	Association of germline variation with the survival of women with BRCA1/2 pathogenic variants and breast cancer. ⁶²	Muranen TA...Nevanlinna H	32964118	2020
43	Retraction: Chemotherapeutic Potential of 2-[Piperidinoethoxyphenyl]-3-Phenyl-2H-Benzo(b)pyran in Estrogen Receptor- Negative Breast Cancer Cells: Action via Prevention of EGFR Activation and Combined Inhibition of PI-3-K/Akt/FOXO and MEK/Erk/AP-1 Pathways. ⁶²	PLOS ONE Editors	32218596	2020
44	High expression of soluble CD155 in estrogen receptor-negative breast cancer. ⁶²	Iguchi-Manaka A...Shibuya K	31372841	2020
45	miRNA551b-3p Activates an Oncostatin Signaling Module for the Progression of Triple-Negative Breast Cancer. ⁶²	Parashar D...Chaluvally-Raghavan P	31875548	2019
46	Galbanic acid: Induced antiproliferation in estrogen receptor-negative breast cancer cells and enhanced cellular redox state in the human dermal fibroblasts. ⁶²	Sajjadi M...Neamati A	31576639	2019
47	GREM1 is associated with metastasis and predicts poor prognosis in ER-negative breast cancer patients. ⁶²	Neckmann U...Holien T	31694641	2019
48	β2-Adrenergic receptor expression is associated with biomarkers of tumor immunity and predicts poor prognosis in estrogen receptor-negative breast cancer. ⁶²	Kurozumi S...Shirabe K	31290053	2019
49	Breast cancer subtypes among Eastern-African-born black women and other black women in the United States. ⁶²	Sung H...Jemal A	31190337	2019
50	Bioinformatics analysis identifies potential chemoresistance-associated genes across multiple types of cancer. ⁶²	Yuan J...Gao J	31402953	2019

Sources

Genes for Estrogen-Receptor Negative Breast Cancer

Genes related to Estrogen-Receptor Negative Breast Cancer (0 elite genes):

(show all 28)

- Elite gene

- Cancer Census gene in COSMIC

#	Symbol	Description	Category	Score	Evidence
1	ESR1	Estrogen Receptor 1	Protein Coding	7.46	DISEASES inferred ¹⁴
2	MIR373	MicroRNA 373	RNA Gene	7.4	DISEASES inferred ¹⁴ ¹⁴
3	MIR10B	MicroRNA 10b	RNA Gene	6.42	DISEASES inferred ¹⁴ ¹⁴
4	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	6.18	DISEASES inferred ¹⁴
5	H2AC18	H2A Clustered Histone 18	Protein Coding	6.08	DISEASES inferred ¹⁴ ¹⁴
6	PGR	Progesterone Receptor	Protein Coding	5.79	DISEASES inferred ¹⁴
7	BRCA1	BRCA1 DNA Repair Associated	Protein Coding	5.49	DISEASES inferred ¹⁴
8	AKT1	AKT Serine/Threonine Kinase 1	Protein Coding	5.41	DISEASES inferred ¹⁴
9	TP53	Tumor Protein P53	Protein Coding	5.3	DISEASES inferred ¹⁴
10	GPER1	G Protein-Coupled Estrogen Receptor 1	Protein Coding	5.23	DISEASES inferred ¹⁴
11	BRCA2	BRCA2 DNA Repair Associated	Protein Coding	5.15	DISEASES inferred ¹⁴
12	CYP19A1	Cytochrome P450 Family 19 Subfamily A Member 1	Protein Coding	5.15	DISEASES inferred ¹⁴
13	EGF	Epidermal Growth Factor	Protein Coding	5.12	DISEASES inferred ¹⁴
14	EGFR	Epidermal Growth Factor Receptor	Protein Coding	5.11	DISEASES inferred ¹⁴
15	CCND1	Cyclin D1	Protein Coding	5.02	DISEASES inferred ¹⁴
16	ORAI3	ORAI Calcium Release-Activated Calcium Modulator 3	Protein Coding	4.98	DISEASES inferred ¹⁴
17	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	4.96	DISEASES inferred ¹⁴
18	CDH1	Cadherin 1	Protein Coding	4.93	DISEASES inferred ¹⁴
19	STAT3	Signal Transducer And Activator Of Transcription 3	Protein Coding	4.89	DISEASES inferred ¹⁴
20	PPIL3	Peptidylprolyl Isomerase Like 3	Protein Coding	4.84	DISEASES inferred ¹⁴
21	FOXA1	Forkhead Box A1	Protein Coding	4.84	DISEASES inferred ¹⁴
22	BCL2	BCL2 Apoptosis Regulator	Protein Coding	4.82	DISEASES inferred ¹⁴
23	AR	Androgen Receptor	Protein Coding	4.82	DISEASES inferred ¹⁴
24	CFAP144	Cilia And Flagella Associated Protein 144	Protein Coding	4.81	DISEASES inferred ¹⁴
25	FLACC1	Flagellum Associated Containing Coiled-Coil Domains 1	Protein Coding	4.74	DISEASES inferred ¹⁴
26	ST6GALNAC2	ST6 N-Acetylgalactosaminide Alpha-2,6-Sialyltransferase 2	Protein Coding	4.74	DISEASES inferred ¹⁴
27	GAPDH	Glyceraldehyde-3-Phosphate Dehydrogenase	Protein Coding	4.69	DISEASES inferred ¹⁴
28	MIR520C	MicroRNA 520c	RNA Gene	4.68	DISEASES inferred ¹⁴

Sources

Variations for Estrogen-Receptor Negative Breast Cancer

Sources

Expression for Estrogen-Receptor Negative Breast Cancer

Search GEO for disease gene expression data for Estrogen-Receptor Negative Breast Cancer.

Sources

Pathways for Estrogen-Receptor Negative Breast Cancer

Pathways related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show top 50) (show all 116)

#	Super pathways	Score	Top Affiliating Genes
1	ERK Signaling ⁶⁴ Show member pathways ILK Signaling ⁶⁴ MAPK Signaling ⁶⁴ Molecular Mechanisms of Cancer ⁶⁴ Rho Family GTPases ⁶⁴	13.91	TP53 STAT3 MYC ESR1 ERBB2 EGFR
2	Signal Transduction ⁶⁶	13.83	TP53 STAT3 PGR MYC H2AC18 GPER1
3	Disease ⁶⁶ Show member pathways Infectious disease ⁶⁶	13.81	AKT1 BRCA1 BRCA2 CCND1 CDH1 CYP19A1
4	GPCR Pathway ⁶⁴ Show member pathways Breast Cancer Regulation by Stathmin1 ⁶⁴ Estrogen Pathway ⁶⁴ NFAT in Immune Response ⁶⁴ P2Y Receptor Signaling ⁶⁴ Pancreatic Adenocarcinoma ⁶⁴ Paxillin Interactions ⁶⁴ Ras Pathway ⁶⁴	13.78	TP53 STAT3 MYC ESR1 ERBB2 EGFR
5	TGF-Beta Pathway ⁶⁴ Show member pathways JAK-STAT Pathway ⁶⁴ JNK Pathway ⁶⁴ MAPK Family Pathway ⁶⁴ Regulation of eIF4 and p70S6K ⁶⁴ SOCS Pathway ⁶⁴	13.62	TP53 STAT3 MYC ERBB2 EGFR EGF
6	Prolactin Signaling ⁶⁴ Show member pathways Development Prolactin receptor signaling ²² EGFR Inhibitor Pathway, Pharmacodynamics ⁶⁰ EGFR tyrosine kinase inhibitor resistance ⁷⁴ ErbB Family Pathway ⁶⁴ ErbB signaling pathway ⁷⁴ ErbB2-ErbB3 Heterodimers ⁶⁴ ErbB4 Pathway ⁶⁴ Estrogen-stimulated signaling through PRKCZ ⁶⁶ Glioblastoma Multiforme ⁶⁴ Glioblastoma signaling pathways ⁷⁴ Growth Hormone Signaling ⁶⁴ HMGB1 Pathway ⁶⁴ IL-2 Pathway ⁶⁴ LPS Stimulated MAPK Signaling ⁶⁴ PACAP Signaling ⁶⁴ PI3K Signaling in B-Lymphocyte ⁶⁴ TCA cycle nutrient use and invasiveness of ovarian cancer ⁷⁴ Thrombopoietin Pathway ⁶⁴ TREM1 Pathway ⁶⁴ UVA-Induced MAPK Signaling ⁶⁴ UVB-Induced MAPK Signaling ⁶⁴ UVC-Induced MAPK Signaling ⁶⁴	13.56	AKT1 BRCA1 BRCA2 CCND1 EGF EGFR
7	Akt Signaling ⁶⁴ Show member pathways p38 Signaling ⁶⁴ Tec Kinases Signaling ⁶⁴	13.48	TP53 STAT3 ERBB2 EGFR EGF CCND1
8	RAF/MAP kinase cascade ⁶⁶ Show member pathways Diseases of signal transduction by growth factor receptors and second messengers ⁶⁶ MAPK family signaling cascades ⁶⁶ MAPK1/MAPK3 signaling ⁶⁶	13.45	STAT3 MYC ESR1 ERBB2 EGFR EGF
9	PIP3 activates AKT signaling ⁶⁶ Show member pathways Intracellular signaling by second messengers ⁶⁶ PTEN Regulation ⁶⁶ Regulation of PTEN gene transcription ⁶⁶ Regulation of PTEN localization ⁶⁶	13.15	TP53 ESR1 ERBB2 EGFR EGF AKT1
10	ESR-mediated signaling ⁶⁶ Show member pathways Estrogen-dependent gene expression ⁶⁶ RUNX1 regulates estrogen receptor mediated transcription ⁶⁶ Signaling by Nuclear Receptors ⁶⁶	13.06	PGR MYC H2AC18 ESR1 EGFR EGF
11	PI3K-Akt signaling pathway ⁷⁴ Show member pathways Focal adhesion: PI3K-Akt-mTOR-signaling pathway ⁷⁴	13.05	TP53 MYC EGFR EGF CCND1 BRCA1
12	Signaling by Receptor Tyrosine Kinases ⁶⁶	12.93	STAT3 PGR MYC ESR1 ERBB2 EGFR
13	Toll-like receptor signaling pathway ⁷⁴ Show member pathways Hepatitis B infection ⁷⁴ Measles virus infection ⁷⁴ Regulation of toll-like receptor signaling pathway ⁷⁴	12.92	TP53 STAT3 MYC CCND1 AKT1
14	Deubiquitination ⁶⁶ Show member pathways Ub-specific processing proteases ⁶⁶	12.9	TP53 MYC H2AC18 ESR1 BRCA1
15	Pre-NOTCH Expression and Processing ⁶⁶ Show member pathways Defective LFNG causes SCDO3 ⁶⁶ Pre-NOTCH Processing in Golgi ⁶⁶ Pre-NOTCH Processing in the Endoplasmic Reticulum ⁶⁶ Pre-NOTCH Transcription and Translation ⁶⁶ Signaling by NOTCH ⁶⁶	12.87	TP53 MYC H2AC18 EGFR EGF CCND1
16	Nuclear receptors meta-pathway ⁷⁴ Show member pathways NRF2 pathway ⁷⁴	12.83	STAT3 MYC ESR1 EGFR CCND1
17	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling ⁶⁶ Show member pathways Constitutive Signaling by Aberrant PI3K in Cancer ⁶⁶ Negative regulation of the PI3K/AKT network ⁶⁶ PI3K/AKT Signaling in Cancer ⁶⁶	12.77	AKT1 EGF EGFR ERBB2 ESR1
18	Malignant pleural mesothelioma ⁷⁴	12.77	AKT1 BRCA1 CCND1 CDH1 EGF EGFR
19	4-1BB Pathway ⁶⁴ Show member pathways CD27 Pathway ⁶⁴ CD40 Signaling ⁶⁴ CMV and MAPK Pathways ⁶⁴ NF-KappaB Activation by EBV ⁶⁴ NF-kappaB Activation by Viruses ⁶⁴ PKR Pathway ⁶⁴ SUMO Pathway ⁶⁴ TNFR2 Pathway ⁶⁴	12.76	TP53 STAT3 EGFR EGF AKT1
20	Overview of interferons-mediated signaling pathway ⁷⁴ Show member pathways all-trans-Retinoic Acid Mediated Apoptosis ⁶⁴ Cytokine Network ⁶⁴ Immune response IFN alpha/beta signaling pathway ²² Interferon alpha/beta signaling ⁶⁶ Jak/STAT Signaling Pathway ⁶⁵ Regulation of IFNA/IFNB signaling ⁶⁶ Type III interferon signaling ⁷⁴	12.73	TP53 STAT3 MYC EGFR EGF AKT1
21	Chks in Checkpoint Regulation ⁶⁴ Show member pathways DNA Repair Mechanisms ⁶⁴ Estrogen-mediated S-Phase Entry ⁶⁴ G2-M Phase Transition ⁶⁴ SREBP Proteolysis ⁶⁴	12.71	BRCA1 BRCA2 CCND1 ESR1 MYC TP53
22	Immune response IL-23 signaling pathway ²² Show member pathways Angiopoietin receptor Tie2-mediated signaling ⁶¹ Angiopoietin-TIE2 Signaling ⁶⁴ Development Angiopoietin - Tie2 signaling ²² Development PDGF signaling via STATs and NF-kB ²² IL23-mediated signaling events ⁶¹ Immune response IL-10 signaling pathway ²² RAC1/PAK1/p38/MMP2 pathway ⁷⁴	12.69	TP53 STAT3 MYC ERBB2 EGFR AKT1
23	Endometrial cancer ⁷⁴ Show member pathways Chromosomal and microsatellite instability in colorectal cancer ⁷⁴ Melanoma ⁷⁴ Non-small cell lung cancer ⁷⁴ Pancreatic adenocarcinoma pathway ⁷⁴ Signal transduction PTEN pathway ²²	12.64	TP53 STAT3 MYC ERBB2 EGFR EGF
24	Development EGFR signaling pathway ²² Show member pathways Development ERBB-family signaling ²² EGF Pathway ⁶⁴ EGFR Signaling Pathway ⁶⁷ ErbB receptor signaling network ⁶¹	12.56	TP53 STAT3 MYC ERBB2 EGFR EGF
25	Hepatocyte growth factor receptor signaling ⁷⁴ Show member pathways Apoptosis and survival Anti-apoptotic action of membrane-bound ESR1 ²² Apoptosis and survival NGF signaling pathway ²² Apoptosis and survival Role of CDK5 in neuronal death and survival ²² Development HGF signaling pathway ²² Development Neurotrophin family signaling ²² Drug-mediated inhibition of MET activation ⁶⁶ MET activates PTPN11 ⁶⁶ MET activates STAT3 ⁶⁶ PLC-gamma1 signalling ⁶⁶ Trk receptor signaling mediated by PI3K and PLC-gamma ⁶¹ TRKA activation by NGF ⁶⁶	12.54	TP53 STAT3 ESR1 ERBB2 CDH1 CCND1
26	WNT Signaling ⁶⁴	12.53	TP53 MYC CDH1 CCND1 AKT1
27	Development Dopamine D2 receptor transactivation of EGFR ²² Show member pathways Chemotaxis CXCR4 signaling pathway ²² Development Alpha-2 adrenergic receptor activation of ERK ²² Extra-nuclear estrogen signaling ⁶⁶	12.52	STAT3 ESR1 EGFR EGF CCND1 AKT1
28	MAPK signaling pathway ⁷⁴	12.51	TP53 MYC EGFR EGF AKT1
29	NF-kappaB Pathway ⁷⁰ Show member pathways Akt Pathway ⁷⁰ Apoptosis Pathway ⁷⁰	12.5	TP53 ERBB2 EGFR AKT1
30	Cell cycle Regulation of G1/S transition (part 1) ²² Show member pathways Cell cycle ESR1 regulation of G1/S transition ²² Cell cycle Role of SCF complex in cell cycle regulation ²² Immune response MIF-JAB1 signaling ²² Mitotic Roles of Polo Like Kinases ⁶⁴	12.48	PGR MYC ESR1 CCND1 BRCA1
31	Development VEGF signaling via VEGFR2 - generic cascades ²² Show member pathways Development VEGF signaling and activation ²² VEGF - VEGF R2 Signaling Pathways ⁶⁵	12.47	AKT1 BRCA1 ESR1 STAT3
32	G-protein signaling RAC1 in cellular process ²² Show member pathways CDC42 signaling events ⁶¹ Cytoskeleton remodeling CDC42 in cellular processes ²² RAC1 signaling pathway ⁶¹	12.46	STAT3 ERBB2 EGFR EGF CDH1
33	Development Ligand-independent activation of ESR1 and ESR2 ²² Show member pathways Transcription CREB pathway ²² Transcription PPAR Pathway ²²	12.42	AKT1 CCND1 EGF EGFR ERBB2 ESR1
34	Development A3 receptor signaling ²² Show member pathways Development A1 receptor signaling ²² G-protein signaling G-Protein alpha-q signaling cascades ²²	12.4	AKT1 CCND1 MYC STAT3
35	Focal adhesion ⁷⁴	12.4	ERBB2 EGFR EGF CCND1 AKT1
36	PDGFR-beta signaling pathway ⁶¹ Show member pathways ErbB1 downstream signaling ⁶¹	12.39	STAT3 MYC EGFR EGF AKT1
37	Development IGF-1 receptor signaling ²² Show member pathways Immune response IL-4 signaling pathway ²² Signal transduction AKT signaling ²²	12.34	TP53 MYC CCND1 AKT1
38	MAPK Signaling: Mitogens ⁶⁵ Show member pathways Akt Signaling Pathway ⁶⁵	12.34	TP53 MYC ERBB2 EGFR CCND1 AKT1
39	p53 Signaling ⁶⁴ Show member pathways p53 Pathway ⁶⁷	12.3	TP53 CCND1 BRCA1 AKT1
40	Signaling by PTK6 ⁶⁶ Show member pathways PTK6 Activates STAT3 ⁶⁶ PTK6 Down-Regulation ⁶⁶ PTK6 Expression ⁶⁶ PTK6 promotes HIF1A stabilization ⁶⁶ PTK6 Regulates Proteins Involved in RNA Processing ⁶⁶ PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases ⁶⁶ PTK6 Regulates RTKs and Their Effectors AKT1 and DOK1 ⁶⁶ Signaling by Non-Receptor Tyrosine Kinases ⁶⁶	12.26	AKT1 CCND1 EGF EGFR ERBB2 STAT3
41	miRNA regulation of DNA damage response ⁷⁴ Show member pathways DNA damage response ⁷⁴	12.23	TP53 MYC CCND1 BRCA1 AKT1
42	Transcription Androgen Receptor nuclear signaling ²² Show member pathways Translation Non-genomic (rapid) action of Androgen Receptor ²²	12.22	STAT3 ERBB2 EGFR EGF CCND1 AKT1
43	Colorectal Cancer Metastasis ⁶⁴	12.22	TP53 STAT3 MYC EGFR EGF CDH1
44	mTOR Signaling ⁶⁵	12.2	AKT1 EGFR ERBB2 TP53
45	Signaling by ERBB4 ⁶⁶ Show member pathways Downregulation of ERBB4 signaling ⁶⁶ ErbB4 signaling events ⁶¹ Nuclear signaling by ERBB4 ⁶⁶	12.2	PGR ESR1 ERBB2 EGFR EGF
46	Signaling by ERBB2 ⁶⁶ Show member pathways Downregulation of ERBB2 signaling ⁶⁶ Downregulation of ERBB2:ERBB3 signaling ⁶⁶ ERBB2 Activates PTK6 Signaling ⁶⁶ ERBB2 Regulates Cell Motility ⁶⁶ GRB7 events in ERBB2 signaling ⁶⁶	12.14	ERBB2 EGFR EGF AKT1
47	MAPK Pathway ⁷⁰ Show member pathways Toll-like Receptor Pathway ⁷⁰	12.14	TP53 STAT3 ERBB2 EGFR AKT1
48	Spinal cord injury ⁷⁴	12.1	TP53 MYC EGFR CCND1
49	Development EGFR signaling via small GTPases ²² Show member pathways Development EGFR signaling via PIP3 ²² Development PDGF signaling via MAPK cascades ²²	12.09	MYC ERBB2 EGFR EGF AKT1
50	Gastrin signaling pathway ⁷⁴	12.07	STAT3 MYC EGFR CDH1 CCND1 AKT1

Sources

GO Terms for Estrogen-Receptor Negative Breast Cancer

Cellular components related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	protein-containing complex	GO:0032991	9.47	TP53 MYC ESR1 EGFR BRCA2 BRCA1
2	nuclear ubiquitin ligase complex	GO:0000152	9.26	BRCA2 BRCA1

Biological processes related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

(show all 27)

#	Name	GO ID	Score	Top Affiliating Genes
1	positive regulation of transcription by RNA polymerase II	GO:0045944	10.53	AKT1 BRCA1 EGFR ESR1 GPER1 MYC
2	positive regulation of cell population proliferation	GO:0008284	10.32	AKT1 CCND1 EGF EGFR ERBB2 GPER1
3	regulation of cell cycle	GO:0051726	10.26	BRCA1 CCND1 GPER1 STAT3 TP53
4	positive regulation of protein phosphorylation	GO:0001934	10.26	GPER1 ERBB2 EGFR CCND1 AKT1
5	positive regulation of DNA-templated transcription	GO:0045893	10.26	TP53 STAT3 MYC ESR1 EGFR EGF
6	negative regulation of gene expression	GO:0010629	10.17	AKT1 ESR1 GPER1 PGR STAT3 TP53
7	response to estradiol	GO:0032355	10.14	STAT3 ESR1 CYP19A1 CCND1
8	epidermal growth factor receptor signaling pathway	GO:0007173	10.11	EGFR EGF AKT1
9	positive regulation of G1/S transition of mitotic cell cycle	GO:1900087	10.1	EGFR CCND1 AKT1
10	cellular response to epidermal growth factor stimulus	GO:0071364	10.1	ERBB2 EGFR AKT1
11	cellular response to estradiol stimulus	GO:0071392	10.08	GPER1 ESR1 EGFR
12	cellular response to ionizing radiation	GO:0071479	10.06	TP53 BRCA2 BRCA1
13	positive regulation of epithelial cell proliferation	GO:0050679	10.04	MYC ERBB2 EGFR EGF
14	response to gamma radiation	GO:0010332	10.02	BRCA2 MYC TP53
15	chromosome organization	GO:0051276	9.97	TP53 MYC BRCA2
16	response to X-ray	GO:0010165	9.95	TP53 CCND1 BRCA2
17	positive regulation of miRNA transcription	GO:1902895	9.95	TP53 STAT3 MYC EGFR
18	mammary gland alveolus development	GO:0060749	9.93	ESR1 EGF CCND1
19	cellular response to indole-3-methanol	GO:0071681	9.9	CDH1 BRCA1
20	positive regulation of RNA polymerase II transcription preinitiation complex assembly	GO:0045899	9.89	TP53 ESR1
21	positive regulation of gene expression	GO:0010628	9.89	TP53 STAT3 PGR MYC GPER1 ERBB2
22	intracellular steroid hormone receptor signaling pathway	GO:0030518	9.85	PGR GPER1 ESR1
23	steroid hormone mediated signaling pathway	GO:0043401	9.83	PGR GPER1 ESR1
24	ERBB2-EGFR signaling pathway	GO:0038134	9.8	EGF EGFR ERBB2
25	chordate embryonic development	GO:0043009	9.79	BRCA2 BRCA1
26	response to UV-A	GO:0070141	9.63	AKT1 CCND1 EGFR
27	cell population proliferation	GO:0008283	9.28	TP53 STAT3 EGFR EGF CCND1 BRCA2

Molecular functions related to Estrogen-Receptor Negative Breast Cancer according to GeneCards Suite gene sharing:

#	Name	GO ID	Score	Top Affiliating Genes
1	identical protein binding	GO:0042802	10.37	TP53 STAT3 PGR ESR1 ERBB2 EGFR
2	steroid binding	GO:0005496	9.8	PGR GPER1 ESR1
3	enzyme binding	GO:0019899	9.8	TP53 PGR ESR1 EGFR CCND1 BRCA1
4	protein phosphatase binding	GO:0019903	9.76	TP53 STAT3 ERBB2 EGFR
5	nuclear estrogen receptor activity	GO:0030284	9.56	ESR1 GPER1
6	nitric-oxide synthase regulator activity	GO:0030235	9.1	ESR1 EGFR AKT1